Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Saline irrigation of the bile duct prevents residual stones

14 Apr 2018
Those with a history of gallstone disease have a 23% increased risk for coronary heart disease.

Preventive saline irrigation of the bile duct (PSIB) appears to be effective in reducing residual stones after endoscopic common bile duct stone (CBD) removal, according to a recent study.

Researchers randomized 148 patients who underwent endoscopic retrograde cholangiopancreatography to either receive (n=73) or not receive (n=75) PSIB after stone removal. Presence of residual stones was evaluated within 6 months after the operation.

Residual stones were reported in 14.9 percent (n=22), five of whom received PSIB (6.8 percent) while 17 did not (22.7 percent). The difference in residual stone incidence rate reached statistical significance (p=0.01).

Multivariate logistic regression analysis revealed that PSIB had a significant protective effect against residual stones following CBD removal (odds ratio [OR], 0.09; 95 percent CI, 0.02–0.45; p=0.003). In contrast, the presence of multiple CBD stones significantly increased the risk of residual stones (OR, 9.40; 1.86–47.54; p=0.007).

A subsequent subgroup analysis showed that PSIB had greater efficacy against residual stones in patients with multiple CBD stones (rate of residual stones, 12.1 percent in PSIB group vs 50.0 percent in non-PSIB group).

The rate of procedure-related complications was 12.8 percent (n=19), the most common of which was pancreatitis. There was no significant difference in the number of patients who experienced complications in the PSIB vs non-PSIB groups (p=0.793). The rate of cholangitis was slightly higher in the PSIB group (5.5 percent vs 2.7 percent), and all patients were given conservative management.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.